Thyroid hormone Synthroid had 57% of the retail market on Aug. 13. FDA set a deadline of Aug. 14 for approved marketing applications for levothyroxine products; Abbott will phase-down its distribution of Synthroid to 95% of current levels by Nov. 1 while its application is pending at FDA (1"The Pink Sheet" July 16, p. 16)
You may also be interested in...
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials